{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05103046",
            "orgStudyIdInfo": {
                "id": "UCT03008-001"
            },
            "organization": {
                "fullName": "1200 Pharma, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1, First in Human, Dose-Escalation Study of UCT-03-008 in Participants With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "first-in-human-study-of-uct-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-10-21",
            "studyFirstSubmitQcDate": "2021-10-21",
            "studyFirstPostDateStruct": {
                "date": "2021-11-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "1200 Pharma, LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Translational Research in Oncology",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 68,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Finding as Monotherapy - Part 1",
                    "type": "EXPERIMENTAL",
                    "description": "UCT-03-008 Dose Finding",
                    "interventionNames": [
                        "Drug: UCT-03-008"
                    ]
                },
                {
                    "label": "Expansion as Monotherapy - Part 2",
                    "type": "EXPERIMENTAL",
                    "description": "UCT-03-008 RP2D Expansion",
                    "interventionNames": [
                        "Drug: UCT-03-008"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "UCT-03-008",
                    "description": "Orally available kinase inhibitor",
                    "armGroupLabels": [
                        "Dose Finding as Monotherapy - Part 1",
                        "Expansion as Monotherapy - Part 2"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events and serious adverse events",
                    "description": "Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "Highest administered dose with \\< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D)",
                    "description": "Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data",
                    "timeFrame": "up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Plasma UCT-03-008 Concentration following single dose (Cmax)",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0(each cycle is 28 days)"
                },
                {
                    "measure": "Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Minimum Plasma UCT-03-008 Concentration following single dose (Cmin)",
                    "description": "PK assessment for UCT-003-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss)",
                    "description": "PK assessment for UCT-003-008",
                    "timeFrame": "Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Time of Maximum Plasma UCT-03-008 Concentration following single dose (Tmax)",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Time of Maximum Plasma UCT-03-008 Concentration at steady state (Tmax,ss)",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Area Under the Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) of UCT-03-008",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Area Under the Plasma Concentration-Time Curve from the time of dosing to the last measurable concentration (AUClast) of UCT-03-008",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Apparent Clearance (CL/F) of UCT-03-008",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Apparent Volume of Distribution (Vz/F) of UCT-03-008",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 0 (each cycle is 28 days)"
                },
                {
                    "measure": "Terminal Half-life (t1/2) of plasma UCT-03-008",
                    "description": "PK assessment for UCT-03-008",
                    "timeFrame": "Cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Time from start of treatment to complete response or partial response",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Time from complete response or partial response to objective disease progression or death due to any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "1 Year Overall Survival (1YOS)",
                    "description": "Proportion of participants alive at 1 year from the start of treatment to death from any cause",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "2 Year Overall Survival (2YOS)",
                    "description": "Proportion of participants alive at 2 years from the start of treatment to death from any cause",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade \u22641\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of UCT-03-008\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History or current evidence/risk of retinopathy\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alex Garcia",
                    "role": "CONTACT",
                    "phone": "213-5197493",
                    "email": "AGarcia@trio-us.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alex Garcia",
                    "affiliation": "TRIO-US",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA - JCCC Clinical Research Unit",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jonathan Goldman, MD",
                            "role": "CONTACT",
                            "phone": "310-923-8712"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Torrance Memorial",
                    "status": "TERMINATED",
                    "city": "Torrance",
                    "state": "California",
                    "zip": "90505",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.83585,
                        "lon": -118.34063
                    }
                },
                {
                    "facility": "Winship Institute of Emory University",
                    "status": "TERMINATED",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Minal Barve, MD",
                            "role": "CONTACT",
                            "phone": "972-566-3000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "START (South Texas Accelerated Research Therapeutics)",
                    "status": "TERMINATED",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}